4basebio (LON:4BB) Shares Down 0.2% – Time to Sell?

4basebio PLC (LON:4BB)’s share price fell 0.2% on Friday . The company traded as low as GBX 501 and last traded at GBX 524. 13 shares traded hands during trading, a decline of 99% from the average session volume of 1,729 shares. The stock had previously closed at GBX 525.

4basebio Stock Performance

The business has a fifty day simple moving average of GBX 501.26 and a two-hundred day simple moving average of GBX 556.46. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52. The company has a market cap of £81.30 million, a PE ratio of -4.82 and a beta of 1.09.

4basebio (LON:4BB) last posted its earnings results on Wednesday, May 20th. The company reported GBX (1.09) earnings per share for the quarter. The business had revenue of GBX 169 million during the quarter. Research analysts anticipate that 4basebio PLC will post -3.43 earnings per share for the current year.

Insider Activity

In other 4basebio news, insider Amy Walker purchased 1,863 shares of 4basebio stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of GBX 509 per share, with a total value of £9,482.67. Insiders own 12.09% of the company’s stock.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.